Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Pluristem Therapeutics Inc. (PSTI - Snapshot Report) recently announced that it will release the results of its phase I/II clinical trial, evaluating the safety and efficacy of PLacental Expanded (PLX-PAD) cells for the treatment of muscle injury, on Jan 21, 2014.

Pluristem develops and manufactures cell therapy products in collaboration with companies like United Therapeutics (UTHR - Analyst Report) or through research and clinical institutions.

The cells from placenta are derived using the company’s proprietary PluriX therapy and are known as PLacental eXpanded cells. Pluristem's first candidate in development, PLX-PAD, is intended to treat peripheral artery disease (PAD).

We note that Pluristem intends to develop and produce cell therapy products for the treatment of multiple disorders using several methods of administration.

The phase I/II study comprised three treatment groups – two PLX-PAD groups of different doses and one placebo group. The study was initiated in Apr 2013. The primary endpoints of the trial were safety and the maximal contraction force of the gluteal muscle at six months post-surgery while the secondary endpoints included an analysis of the macrostructure and microstructure of the gluteal muscle using magnetic resonance imaging (MRI) and biopsy.

A positive outcome from this study will enable Pluristem to further evaluate the potential of PLX-PAD cells for this indication along with other potential surgical orthopedic injuries and non-surgical sports related injuries. We expect investor focus on results from the trial.

Pluristem currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the same sector include Forest Laboratories (FRX - Analyst Report) and Lannett Company, Inc. (LCI - Snapshot Report) with a Zacks Rank #1 (Strong Buy).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 33.21 +7.92%
E COMMERCE C DANG 12.50 +4.52%
E*TRADE FINA ETFC 21.23 +4.25%
BIO PATH HOL BPTH 2.87 +4.18%
DIXIE GROUP DXYN 14.58 +3.70%